Abeona Therapeutics initiated with a Buy at Seaport Global. Seaport Global analyst Vernon Bernardino initiated Abeona Therapeutics with a Buy and $29 price target saying its “powerful” R&D engine leverages AAV vector technology to create gene therapies for rare diseases. Bernardino said Abeona has generated six candidate gene therapies, including three in Phase 1/2 clinical trials, and has first-mover potential in each targeted therapeutic area plus premium pricing potential for its products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.